“Design, Development and Characterization of Paclitaxel Loaded Solid Lipid Nanoparticles as a Colloidal Drug Carrier”
Keywords:
Paclitaxel, Solid Lipid nanoparticles, optimization,, 32 Full Factorial Design, Particle sizeAbstract
Paclitaxel is a chemotherapeutic agent used in the treatment of different malignancies. Paclitaxel has limited bioavailability due to its poor aqueous solubility and it also shows harmful effects on various organs. This study is aimed to design and characterize Paclitaxel loaded SLNs are colloidal drug delivery in sustained manner with high degree of specificity. Paclitaxel loaded solid lipid nanoparticles fabricated by Microemulsion followed by probe sonication technique using Stearic acid as lipid and stabilized of Mixture of surfactants. In this study 32 Full Factorial design was employed for optimizing the concentration of lipid as Stearic acid and Surfactant (Soya lecithin) for the nanoparticles. The optimization was done by studying the dependant variable of particle size and % Entrapment Efficiency. The results showed that the Paclitaxel loaded solid lipid nanoparticles prepared with the concentration 33.31 % Stearic acid and 500 mg of Soya lecithin was optimum characteristic than other formulations. They showed the average particles size 149 ±4.10 nm and PDI 250±2.04.The zeta potential, % EE and % Drug loading capacity was found to be respectively -29.7 , 93.38±1.90 and 0.81 ± 0.01.The optimized batch of Paclitaxel SLNs exhibited spherical shape with smooth surface analyzed by Transmission Electron Microscopy .In vitro study showed sustained release profile and was found to follow Higuchi Kinetics Equation. The SLNs of Paclitaxel met all the requirements of a colloidal drug delivery system. They had particle size in nanosize; their size distribution was narrow and all the particles were in spherical shape.
References
Wani M, Taylor H, Wall M, Coggon P, McPhail A. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc.1971; 93 (9): 2325–2327.
Hawkins MJ. New anticancer agents: taxol, camptothecin analogs,and anthrapyrazoles. Oncology 1992;6:17–23.
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797–805.
Markman M. Taxol: an important new drug in the management of epithelial ovarian cancer. Yale J Biol Med 1991;64:583–90.
Sung FL, Poon TC, Hui EP, Ma BB, Liong E, To KF, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 2005;19: 237–45.
Spencer and Faulds, Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer, Adis International Limited, Auckland, New Zealand, 1994; 48(5): 794-847.
Saville M.W., Lietzau J., Pluda J.M., Wilson W.H., Humphrey R.W., Feigel E., Steinberg S.M., Broder S. et al.. Treatment of HIVassociated Kaposi's sarcoma with paclitaxel. The Lancet. 1995; 346 (8966): 26–28.
Trissel LA, Xu QA, Gilbert DL. Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions. Ann Pharmacother 1998; 32:1013–6.
Zhang Y, Xu QA, Trissel LA, Gilbert DL, Martinez JF. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother 1997;31: 1465–70.
Xiaowei Dong a, Cynthia A. Mattingly a, Michael Tseng b, Moo Cho c, Val R. Adams a, Russell J. Mumper, Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization, European Journal of Pharmaceutics and Biopharmaceutics 2009;72 :9–17.
R. Pasqualini, W. Arap, D.M. McDonald, Probing the structural and molecular diversity of tumor vasculature, Trends Mol. Med. 2002;8 (120: 563–571.
S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA1998 ; 95 (8):4607–4612.
M.C. Gohel, A.F. Amin, Formulation optimization of controlled release diclofenac sodium microspheres using factorial design, J. Control Release 1998;51(2–3) : 115–122.
M.D. Bhavsar, S.B. Tiwari, M.M. Amiji, Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design, J. Control Release 2006;110 (2) : 422–430.
A.Dinda, I. Biswal, P.Chowdhury, R. Mohapatra, Formulation Development and Evaluation of Paclitaxel loaded solid lipid nanoparticles using glyceryl Monostearate, Journal of applied pharmaceutical science 2013;3:133-138.
D. Pandita, A. Ahuja, T. Velpandian, V. Lather, T. Dutta, R. K. Khar, Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique, Pharmazie,2009;64: 5.
Sidharth M Patil, and Hemant P Joshi , Research Journal of Pharmaceutical, Optimizing the Concentration of Ampiphiles in the Development of Colloidal Drug Carriers for Paclitaxel. Biological and Chemical Sciences, 2013;4(3):1066-80.
Hoo-Kyun Choia,b ,Robhash Kusam Subedi a, Keon Wook Kanga, ,Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin, European Journal of Pharmaceutical Sciences 37 (2009) 508–513.
